VX-522 Nebuliser dispersion, Kalydeco 150 mg film-coated tablets clinical trials

A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

This study is testing a new inhaled medicine, VX-522, for adults with cystic fibrosis (CF) whose current treatments aren't working well. Researchers want to see if it's safe and helpful. It's an early-stage trial, meaning it's one of the first times this medicine is being tested in people.